Clinical trials · New York
Cancer clinical trials in New York
We’re tracking 1,365 recruiting cancer studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
New York, New YorkAges 18 years+ - NCT06799065RecruitingPhase 1/Phase 2
Oral drug for advanced solid tumors including ovarian cancer
This trial tests a new daily pill that targets a protein helping cancer cells divide. It may stop tumors from growing in people with advanced or metastatic cancer that has returned or stopped responding to standard treatments, including some types of ovarian, lung, and other solid tumors.
Long Island City, New YorkAges 18 years+ - NCT06774963RecruitingPhase 1
Study of LNCB74 for advanced solid tumors
This trial tests a new drug called LNCB74 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective.
Buffalo, New YorkAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
New York, New YorkAges 18 years+ - NCT06733363RecruitingPhase 2
Vegetable diet to prevent bladder cancer return
This trial tests whether a diet rich in cruciferous vegetables (like broccoli, cauliflower, and kale) can help prevent bladder cancer from coming back or getting worse. It is for people with early-stage, non-invasive bladder cancer who live in New York State.
Buffalo, New YorkAges 18 years+ - NCT06733350RecruitingPhase 4
Testosterone therapy for low testosterone in men with low-risk prostate cancer
This study tests whether testosterone replacement therapy can safely improve low testosterone levels in men with low-risk prostate cancer who are not getting immediate treatment. It aims to help men feel better without worsening their cancer.
Buffalo, New YorkAges 18 years+ - NCT06721065Recruiting
Study of interpretation services for breast cancer patients
This study tests different ways of providing language interpretation during breast cancer or gastrointestinal cancer visits at MSK. It aims to improve communication for patients who prefer Spanish or Mandarin and have limited English proficiency.
Rockville Centre, New YorkAges 18 years+ - NCT06710756RecruitingPhase 1/Phase 2
Lead-212 therapy for solid tumors
This trial tests a new radioactive drug, Lead-212 PSV359, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to find and attack cancer cells.
New York, New YorkAges 18–90 - NCT06589804RecruitingPhase 3
Testing cetuximab plus pembrolizumab for advanced head and neck cancer
This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).
Commack, New YorkAges 18 years+ - NCT06563388RecruitingPhase 3
SABR for limited metastatic cancer (ID-COMET trial)
This study tests a precise radiation technique called SABR to treat cancer that has spread to a few spots. It aims to see if this approach can help control the cancer better than usual treatment, especially for lung, prostate, colorectal, or other solid tumors with limited spread.
Buffalo, New YorkAges 1 year+ - NCT06559059Recruiting
Virtual cancer program for Veterans with new cancer
This study looks at how well a virtual (telemedicine) cancer program works for Veterans who are newly diagnosed with lung, prostate, breast, or colon cancer. Participation involves a telemedicine visit at a VA medical center instead of traveling to the hospital.
Brooklyn, New YorkAges 18 years+ - NCT06545331RecruitingPhase 1
A study of XB010 for advanced solid tumors
This trial tests an investigational drug called XB010 for people with solid tumors that have spread or cannot be removed by surgery. It aims to see if XB010 is safe and effective for several cancer types, including lung, breast, head and neck, and esophageal cancers.
The Bronx, New YorkAges 18 years+ - NCT06533826RecruitingPhase 2
Testing two antibody drugs for HER2-low breast cancer
This trial tests two antibody-drug conjugates (Enhertu and Datroway) for breast cancer that is HER2-low or HER2-0. It aims to find the best treatment sequence for people whose cancer has stopped responding to prior therapy.
The Bronx, New YorkAges 18 years+ - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
New York, New YorkAges 18 years+ - NCT06287775RecruitingPhase 1/Phase 2
Testing a new drug combo for small cell lung cancer
This trial tests adding a new drug, iadademstat, to standard immunotherapy drugs (atezolizumab or durvalumab) for people with small cell lung cancer that responded to initial treatment. The goal is to see if this combination works better at preventing cancer from returning.
New York, New YorkAges 18 years+ - NCT06275126Recruiting
Choosing the Best Surgery for Young Women with Breast Cancer
This study looks at how to make the best surgical choices for young women with breast cancer. It compares different surgery options to help guide treatment decisions.
New York, New YorkAges 18–44 - NCT06096844RecruitingPhase 3
Chemotherapy plus immunotherapy vs. immunotherapy alone for older adults with lung cancer
This study compares getting both chemotherapy and immunotherapy versus immunotherapy alone for older adults with advanced lung cancer. The goal is to see which approach is more effective and tolerable for people aged 70 and older.
Glens Falls, New YorkAges 70 years+ - NCT06072612RecruitingPhase 3
Bria-IMT plus CPI vs standard care for advanced breast cancer
This trial tests a new combination of two immunotherapy drugs (Bria-IMT and a checkpoint inhibitor) against your doctor's choice of standard treatments. It is for people with advanced breast cancer that has spread and who have already tried several prior therapies.
Babylon, New YorkAges 18 years+ - NCT05859074RecruitingPhase 1
Testing MQ710 injections alone or with pembrolizumab for advanced cancers
This early-phase study tests MQ710, a medicine given by injection into a reachable tumor, to see how well it can control advanced cancers. Some participants also receive pembrolizumab, an immunotherapy, to help the immune system fight the cancer.
Commack, New YorkAges 18 years+ - NCT05846789RecruitingPhase 2
Tocilizumab plus chemo for metastatic breast cancer
This trial tests whether adding tocilizumab, a drug that calms the immune system, to standard chemotherapy helps control certain advanced breast cancers. It is for people with triple-negative or ER-positive, HER2-negative breast cancer that has spread or come back.
Buffalo, New YorkAges 18 years+ - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
New York, New YorkAges 18 years+ - NCT05422794RecruitingPhase 1
Adding a new drug plus pembrolizumab to standard chemo for TNBC
This trial studies whether adding a new anti-cancer drug (ZEN-3694) and the immunotherapy drug pembrolizumab to standard chemotherapy (nab-paclitaxel) can work better for advanced triple-negative breast cancer. It’s testing safety first (Phase 1) and, for some patients, how well the treatment controls the cancer.
New York, New YorkAges 18 years+ - NCT05419076RecruitingPhase 2
SRS radiation for small cell lung cancer with brain spread
This Phase 2 trial tests a type of focused radiation (stereotactic radiosurgery, or SRS) for people with small cell lung cancer that has spread to the brain. It looks at whether this approach can treat brain metastases when the cancer has limited to a certain number of spots.
Commack, New YorkAges 18 years+ - NCT05351424Recruiting
Spanish-language cancer care support for breast or prostate radiation
This study tests an educational and communication support program to help Spanish-speaking people stay on track with treatment when they’re getting radiation for non-spread (non-metastatic) breast or prostate cancer. It may help by improving understanding through interpreter-supported visits.
New York, New YorkAges 18 years+
Cancer trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 9 studies
- Memorial Sloan Kettering Nassau · 5 studies
- Memorial Sloan Kettering Westchester · 5 studies
- NYU Langone Health · 5 studies
- Roswell Park Comprehensive Cancer Center · 5 studies
- Columbia University Irving Medical Center · 2 studies
- Glens Falls Hospital · 2 studies
- Memorial Sloan Kettering Commack · 2 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in New York?
- Yes. We're currently tracking 1,365 recruiting cancer studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.